


Data Sheet

Product Name:	Poloxime
Cat. No.:	CS-1334
CAS No.:	17302-61-3
Molecular Formula:	C ₁₀ H ₁₃ NO ₂
Molecular Weight:	179.22
Target:	Polo-like Kinase (PLK)
Pathway:	Cell Cycle/DNA Damage
Solubility:	H ₂ O : < 0.1 mg/mL (insoluble); DMSO : ≥ 100 mg/mL (557.97 mM)



BIOLOGICAL ACTIVITY:

Poloxime, a hydrolysis product of poloxin, is a non-ATP-competitive **Plk1** inhibitor, with moderate Plk1 inhibitory activity. IC₅₀ & Target: PLK1^[1] **In Vitro:** Poloxime (100 μM) inhibits phosphopeptide binding to polo-box domain (PBD) of polo-like kinase 1 (Plk1)^[2].

References:

[1]. Liu M, et al. Identification of indole-3-carboxylic acids as non-ATP-competitive Polo-like kinase 1 (Plk1) inhibitors. *Bioorg Med Chem Lett*. 2015 Feb 1;25(3):431-4.

[2]. Yin Z, et al. Thymoquinone blocks pSer/pThr recognition by Plk1 Polo-box domain as a phosphate mimic. *ACS Chem Biol*. 2013 Feb 15;8(2):303-8.

CAIndexNames:

2,5-Cyclohexadiene-1,4-dione, 2-methyl-5-(1-methylethyl)-, 1-oxime

SMILES:

CC1=CC(C(C)C)=C/C1=N\O)=O

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 732-484-9848 Fax: 888-484-5008 E-mail: sales@ChemScene.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA